Cohort of Patients With Chronic Myelomonocytic Leukemia
Gustave Roussy, Cancer Campus, Grand Paris
5,000 participants
Mar 1, 2026
OBSERVATIONAL
Conditions
Summary
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.
Eligibility
Inclusion Criteria5
- Adults aged 18 years and over
- Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
- Confirmed diagnosis of chronic myelomonocytic leukemia
- Regardless of stage (chronic or transformed), and whether or not currently being treated
- Signed informed consent
Exclusion Criteria2
- Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
- Refusal informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood samples taken as part of a scheduled assessment within the context of medical care * Standard sample: 2 x 10 mL EDTA tubes * For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care * Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue sample will be considered in consultation with the surgeon (affected tissue, surrounding healthy tissue).
Locations(24)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07512882